CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 600 enrolled
Drug / intervention
iclaprim +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02600611
NCT02600611Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1

Motif Bio·interventional·Posted Nov 9, 2015·Updated Jun 19, 2018

In Brief

A Phase 3 clinical trial evaluating iclaprim and vancomycin for Skin Structures and Soft Tissue Infections. Completed, enrolled 600 participants across 56 sites in 10 countries.

Detailed Summary

This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Structures and Soft Tissue Infections
CountriesBulgaria, Chile, Colombia, Germany, Latvia, Peru, Poland, Puerto Rico, Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 9, 2015
Enrollment StartNov 1, 2015
Primary CompletionJan 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.6 years ago

Interventions

iclaprimdrug

Experimental treatment

vancomycindrug

Active comparator